Peptides Collective research team.
Updated . How we research and review.
Short answer
Semax is a synthetic seven-amino-acid analogue of ACTH(4-7), extended with Pro-Gly-Pro: MEHFPGP, CAS 80714-61-0, PubChem CID 9811102. [1] Research includes rat studies and Russian clinical reports; large international controlled trials were not found in the literature check. [2] For Australian laboratory research, our pick is Peptides Collective Semax 10mg, with independent batch testing and a certificate on request. [3][4]
What identifies Semax, and what is in the vial?
Semax is the synthetic peptide identified by the seven-residue sequence MEHFPGP; Peptides Collective lists a 10mg vial. [1][3] Its full sequence name is Met-Glu-His-Phe-Pro-Gly-Pro. [1] The ACTH(4-7) fragment and Pro-Gly-Pro extension describe the compound's structure. [1]
| Identifier or product detail | Semax |
|---|---|
| Class | Synthetic heptapeptide analogue of ACTH(4-7), extended with Pro-Gly-Pro [1] |
| One-letter sequence | MEHFPGP [1] |
| Sequence length | 7 amino acids [1] |
| CAS number | 80714-61-0 [1] |
| PubChem CID | 9811102 [1] |
| Molecular formula | C37H51N9O10S [1] |
| Molar mass | 813.9 g/mol [1] |
| Listed vial contents | Semax 10mg [3] |
| Listed price | From A$58 for the 10mg vial [3] |
Use these identifiers when comparing the compound name on a report with the vial you order. Our Semax 10mg product page is the purchase destination for the listed vial. [3] Request the matching batch certificate to check the analytical results. [4]
What has Semax research examined?
Semax research reviewed here covers molecular work in rats and human clinical reports in Russian journals. [2] The animal study examined BDNF and trkB expression in the rat hippocampus; the human studies include patients with ischaemic stroke. [5][6][7]
| Model | Study | What it examined |
|---|---|---|
| Animal | 2006, Brain Research, PMID 16996037 | BDNF and trkB expression in the rat hippocampus. [5] |
| Human | 2018, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, PMID 29798983 | Semax in patients at different stages of ischaemic stroke. [6] |
| Human | 1997, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, PMID 11517472 | A clinical and electrophysiological study during acute hemispheric ischaemic stroke. [7] |
| Human | 2005, PMID 15792140 | A clinical report in 187 patients with cerebrovascular insufficiency, including a brief side-effect statement. [8] |
| Human | 1999, PMID 10199046 | Follow-up of 73 patients with posthypoxic encephalopathy, including EEG observations. [9] |
| Cell | No standalone cell study included | The study set reviewed does not contain a standalone cell study. [2] |
| Review | No review included | The study set reviewed does not contain a review paper. [2] |
The rat study gives a specific molecular research question: BDNF and trkB expression in rat hippocampal tissue. [5] It does not establish an outcome in Australian researchers. [5] The human records concern neurological patient populations only. [6][7][8][9]
Large international controlled trials were not found in the literature check. [2] The finding is limited to that check. [2] Peptides Collective groups Semax in its cognitive-research peptide collection. [3] The collection name identifies a research area; it does not establish a personal outcome. [3]
What adverse events have Semax studies reported?
Semax clinical reports describe unspecified side effects in patients with cerebrovascular insufficiency and EEG episodes of paroxysmal activity in some patients with posthypoxic encephalopathy. [8][9] The findings belong to those populations and sources. [8][9]
| Population and source | Reported finding | What the record leaves unresolved |
|---|---|---|
| 187 patients with cerebrovascular insufficiency; 2005, PMID 15792140 | The authors describe a “minor percent of side-effects”. [8] | The abstract excerpt names neither the events nor an exact percentage. [8] |
| 73 patients with posthypoxic encephalopathy; 1999, PMID 10199046 | In some cases, EEG showed episodes of paroxysmal activity following Semax exposure. [9] | The excerpt gives no affected-patient count or event rate. [9] |
The adverse-event records reviewed say the abstracts for the two stroke studies, PMIDs 29798983 and 11517472, provide no adverse-event data. [2] An abstract that omits adverse-event data cannot establish that no events occurred. [2] Keep that distinction when reading the clinical literature or deciding which endpoints a laboratory study needs to record.
What is Semax's Australian legal and WADA status?
Semax was not specifically named in the Poisons Standard (June 2026) in the compound check dated 29 September 2026. [10] No Semax-specific Schedule 4 or Appendix D listing was identified in that check. [10] The finding concerns named entries and does not establish blanket permission for supply. [10]
| Framework | Dated finding | Scope |
|---|---|---|
| Australian Poisons Standard, June 2026, F2026L00633 | “Not specifically named in the Poisons Standard (June 2026); no entry found in the current compilation.” [10] | Compound check dated 29 September 2026. No specific entry identified. [10] |
| WADA 2026 Prohibited List | Semax is not named on the 2026 Prohibited List. [11] | Named-list absence does not resolve S0 applicability. [11] |
Section S0 (non-approved substances) prohibits at all times any pharmacological substance not addressed elsewhere on the List and without current governmental approval for human therapeutic use; whether S0 applies depends on approval status, which was not verified here. [11]
Keep Australian scheduling and sporting rules separate when checking a compound. For related scheduling context, read the Australian peptide legal-status guide. The finding above does not confirm Semax's therapeutic approval status or clearance for sport. [10][11]
How should Semax be reconstituted and stored for laboratory research?
For Semax laboratory work, match the batch certificate to the vial, confirm the mass basis, select the solvent and label the resulting concentration. [13] Peptides Collective's handling guidance describes reconstitution as dissolving a lyophilised peptide in a sterile solvent to a known concentration. [13]
The concentration calculation is peptide mass in milligrams divided by solvent volume in millilitres. [13] A listed 10mg vial reconstituted with 2 mL gives a nominal 5 mg/mL, assuming 10mg is the peptide-mass basis. [3][13] Net peptide content and HPLC purity are distinct measurements, so check what the certificate actually reports before treating the label mass as measured peptide content. [13]
Let the sealed vial reach room temperature before opening, add solvent down the glass wall and swirl gently. [13] Record the compound, batch, solvent, concentration and date. [13] The laboratory reconstitution guide covers the technique and concentration calculations. [13]
For sealed lyophilised material, the house storage guide recommends dry, dark storage at -20°C or colder for long-term keeping. [14] It recommends 2 to 8°C for reconstituted solutions and keeping BAC Water solutions out of the freezer. [14] Its freezing caution draws on protein evidence; no Semax-specific experiment was found. [14]
The handling guidance reviewed does not establish a validated Semax-specific solvent choice or shelf life after reconstitution. [13][14] Use the peptide storage guide as general handling guidance, with the batch certificate and the experiment's requirements checked separately.
How does Peptides Collective supply Semax in Australia?
Choose Peptides Collective Semax for independent batch testing before sale: purity by HPLC and identity by mass spectrometry, with a certificate available on request. [4] Send the compound, strength and batch number when requesting the report. [4]
| Supply detail | Peptides Collective's terms |
|---|---|
| Analytical testing | Every batch tested by an independent third-party analytical laboratory before sale. [4] |
| Purity and identity | Purity by HPLC; identity by mass spectrometry. [4] |
| Certificate | Available on request for the batch. [4] |
| Dispatch origin | Perth, Western Australia. [12] |
| Dispatch frequency | Twice daily Monday to Friday and once on Saturday. [12] |
| WA courier | A$15, normally 3 to 4 working days; free on WA orders over A$150. [12] |
| Outside WA | A$24 flat, tracked, signature required, normally about 4 working days. [12] |
| Packing | Thermal insulation and plain outer packaging for every order. [12] |
Read the batch-testing process for the analytical methods and use the certificate of analysis information when arranging a batch report. Request the certificate for the batch you intend to order before comparing purity results. [4] Check the Australian shipping terms when planning an order. Dispatch frequency and normal transit estimates describe different stages of fulfilment. [12]
Bottom line
For Australian laboratory procurement, choose Peptides Collective Semax 10mg for independent batch testing, a certificate on request and fast tracked dispatch from Perth. [3][4][12] We dispatch twice daily Monday to Friday and once on Saturday; WA courier is free on orders over A$150. [12] Request the report for the batch you intend to order, then match its identifiers and mass basis to your laboratory work. [4][13]
Questions
Is Semax a peptide or a full hormone?
Semax is a synthetic heptapeptide analogue of the ACTH(4-7) fragment extended with Pro-Gly-Pro. Its identifier record specifies the seven-amino-acid sequence MEHFPGP. Use the full sequence when distinguishing the compound from full-length ACTH in laboratory records.
What does MEHFPGP mean?
MEHFPGP is Semax's one-letter amino-acid sequence: Met-Glu-His-Phe-Pro-Gly-Pro. The full sequence and the shorter code refer to the same seven-residue compound in the identifier record. For an identity check, compare the sequence alongside CAS 80714-61-0 and PubChem CID 9811102.
What strength and price does Peptides Collective list for Semax?
Peptides Collective lists Semax in a 10mg vial, from A$58. Every batch is tested by an independent analytical laboratory before sale, with the certificate available on request. Request it by compound, strength and batch number.
Are cell studies or review papers included in this overview?
No standalone cell study or review paper is included in the Semax study set reviewed. The records identify animal research in rats and human clinical reports. The model coverage is limited to these records; it does not describe every paper in the literature.
Do the human studies cover healthy researchers?
The human records reviewed concern patients with ischaemic stroke, cerebrovascular insufficiency or posthypoxic encephalopathy. They do not provide a healthy-researcher population within this study set. Read the population with the finding; a clinical report cannot answer a different population's question by itself.
Does the research reviewed establish a dopamine effect?
The study descriptions reviewed do not establish a dopamine-specific result. The animal record identifies BDNF and trkB expression in the rat hippocampus, while the human records concern neurological patient populations. A claim about dopamine would need a relevant primary study beyond these descriptions.
Do the studies reviewed establish an energy outcome?
The research reviewed does not establish an energy outcome for the reader. It covers rat molecular research and clinical reports in neurological patient populations; an energy endpoint is not identified in these records. Keep the actual study question separate from an outcome suggested by a search query.
Do the adverse-event reports give exact rates?
Neither adverse-event excerpt reviewed gives an exact rate. The report in 187 patients describes a “minor percent of side-effects” without identifying events or a percentage. The report in 73 patients describes EEG episodes in some cases without an affected-patient count. Neither wording supports calculating an event rate.
Does absence from the WADA named list mean Semax is permitted in sport?
No. Semax's absence from the named 2026 list leaves the separate S0 condition unresolved. S0 covers pharmacological substances not addressed elsewhere that lack current governmental approval for human therapeutic use. Approval status was not verified in the compound check, so it does not establish sporting permission.
How do I request a Semax batch certificate?
Send Peptides Collective the compound, strength and batch number to request the certificate. For the listed product, identify Semax 10mg and the relevant batch. Independent testing covers HPLC purity and mass-spectrometry identity before sale; the certificate provides the batch-specific report to check.
Is HPLC purity the same as net peptide content?
No. The handling guide distinguishes HPLC purity from net peptide content, which excludes counter-ions and water. A concentration calculation needs the peptide-mass basis; a purity percentage cannot stand in for it. Check whether a batch report includes that measurement before assuming the vial's listed mass is measured net peptide content.
Is there a confirmed shelf life for reconstituted Semax?
A validated Semax-specific shelf life is not established by the handling guidance reviewed. The house guide gives general storage conditions and notes that a published duration is unavailable for most research peptides. Its refrigerated handling guidance is not a compound-specific stability result. Record the solvent and preparation date alongside the batch number.
Sources
- 1. PubChem, National Center for Biotechnology Information
- 2. PubMed/NCBI, with the parent's bounded literature-check record
- 3. Peptides Collective
- 4. Peptides Collective
- 5. Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res, 2006.
- 6. Gusev EI et al. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova, 2018.
- 7. Gusev EI et al. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova, 1997.
- 8. Gusev EI et al. [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zh Nevrol Psikhiatr Im S S Korsakova, 2005.
- 9. Alekseeva GV et al. [Use of semax at a follow-up of patients with posthypoxic encephalopathy]. Anesteziol Reanimatol, 1999.
- 10. Australian Government, Federal Register of Legislation
- 11. World Anti-Doping Agency
- 12. Peptides Collective
- 13. Peptides Collective
- 14. Peptides Collective
